

14 Nov 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Pfizer's "game-changing" COVID-19 oral antiviral results; Novartis sells Roche stake; Novartis trumps productive pipeline; Bayer sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 November 2021, including: [Pfizer Inc.](#)'s game-changing COVID oral antiviral results; [Novartis AG](#) sells [Roche Holding AG](#) stake; Novartis trumps productive pipeline; [Bayer AG](#) sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pfizer's Oral COVID-19 Pill Paxlovid Tops Merck's Molnupiravir](#)" - Scrip, 5 Nov, 2021.)

(Also see "[A Win-Win As Novartis Sells Roche Stake](#)" - Scrip, 4 Nov, 2021.)

(Also see "[Tsai Trumpets Productivity of Novartis Pipeline](#)" - Scrip, 10 Nov, 2021.)

(Also see "[Bayer Backs Hot Flashes Drug For Blockbuster Status](#)" - Scrip, 9 Nov, 2021.)

(Also see "[Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It](#)" - Scrip, 11 Nov, 2021.)

[Click here to explore this interactive content online](#) 